ProQR (PRQR)
NASDAQ:PRQR
Want to see PRQR full AI Analyst Report?
Top Page
ProQR
(NASDAQ:PRQR)
Select Model
Select Model
Rating:45Neutral
Price Target:
$1.50
▼(-24.62% Downside)
Action:Reiterated
Date:05/14/26
Overall score is held down primarily by weak financial performance—large ongoing losses, meaningful cash burn, and declining TTM revenue—despite moderate leverage. Technical indicators are broadly neutral with limited momentum, and valuation is constrained by negative earnings and no provided dividend yield.
Positive Factors
High Gross Margin
A TTM gross margin near 96% indicates the Axiomer platform yields high product-level economics once a candidate is commercialized. This durable structural advantage can support scalable margins as pipeline assets advance, helping future profitability if clinical programs convert to revenues.
Negative Factors
Heavy Cash Burn
Sustained negative operating and free cash flow near -$48M TTM means the business is not self-funding and will rely on external capital to advance programs. Persistent burn elevates dilution risk, limits strategic flexibility, and makes long-term execution contingent on successful financing or partnership outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margin
A TTM gross margin near 96% indicates the Axiomer platform yields high product-level economics once a candidate is commercialized. This durable structural advantage can support scalable margins as pipeline assets advance, helping future profitability if clinical programs convert to revenues.
Read all positive factors
ProQR (PRQR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$167.52M
Dividend YieldN/A
Average Volume (3M)534.76K
Price to Earnings (P/E)―
Beta (1Y)2.07
Revenue Growth-23.73%
EPS Growth-44.36%
CountryUS
Employees166
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.44
Shares Outstanding105,361,060
10 Day Avg. Volume796,312
30 Day Avg. Volume534,757
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)3.67
Price to Sales (P/S)11.85
P/FCF Ratio-3.50
Enterprise Value/Market Cap0.41
Enterprise Value/Revenue5.14
Enterprise Value/Gross Profit5.73
Enterprise Value/Ebitda-1.59
Forecast
1Y Price Target
$8.20Price Target Upside312.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.52
Revenue Forecast (FY)$22.76M
ProQR Business Overview & Revenue Model
Company Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate tri...
How the Company Makes Money
null...
ProQR Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
46
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.44M | 15.28M | 18.91M | 6.51M | 3.59M | 1.33M |
| Gross Profit | 12.06M | 12.68M | 18.91M | 6.51M | 3.59M | 1.33M |
| EBITDA | -43.44M | -39.56M | -24.12M | -24.10M | -56.46M | -54.95M |
| Net Income | -36.79M | -40.52M | -27.76M | -28.12M | -64.42M | -60.74M |
Balance Sheet | ||||||
| Total Assets | 99.14M | 112.71M | 167.96M | 152.31M | 171.32M | 209.58M |
| Cash, Cash Equivalents and Short-Term Investments | 81.17M | 92.37M | 149.41M | 131.37M | 94.78M | 187.52M |
| Total Debt | 13.70M | 13.99M | 17.22M | 21.80M | 21.97M | 60.37M |
| Total Liabilities | 61.50M | 63.36M | 79.40M | 106.59M | 104.64M | 96.35M |
| Stockholders Equity | 37.64M | 49.35M | 88.56M | 45.72M | 67.06M | 113.83M |
Cash Flow | ||||||
| Free Cash Flow | -48.99M | -51.69M | -37.81M | 20.18M | -69.22M | -26.50M |
| Operating Cash Flow | -48.04M | -50.71M | -36.39M | 21.55M | -68.51M | -26.01M |
| Investing Cash Flow | -955.79K | -979.74K | -4.07M | 4.28M | -702.00K | -425.00K |
| Financing Cash Flow | -1.63M | -1.76M | 70.28M | -2.27M | -30.89M | 136.83M |
ProQR Technical Analysis
Negative
1.99
Price Trends
1.69
Negative
1.69
Negative
1.98
Negative
Market Momentum
-0.03
Positive
41.99
Neutral
36.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRQR, the sentiment is Negative. The current price of 1.99 is above the 20-day moving average (MA) of 1.61, above the 50-day MA of 1.69, and above the 200-day MA of 1.98, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 41.99 is Neutral, neither overbought nor oversold. The STOCH value of 36.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PRQR.
ProQR Risk Analysis
ProQR disclosed 81 risk factors in its most recent earnings report. ProQR reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ProQR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $316.04M | -6.54 | -20.31% | ― | 8.21% | 21.41% | |
54 Neutral | $223.61M | -4.25 | -68.09% | ― | 56.76% | 63.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $328.11M | -2.34 | -57.01% | ― | ― | -28.75% | |
45 Neutral | $167.52M | -2.71 | -86.47% | ― | -23.73% | -44.36% | |
44 Neutral | $160.89M | -4.68 | -1115.29% | ― | 1.48% | -244.25% |
* Healthcare Sector Average
PRQR
ProQR
1.51
-0.20
-11.70%
CDXS
Codexis
2.55
0.12
4.94%
HRTX
Heron Therapeutics
0.86
-1.06
-55.26%
TLSA
Tiziana Life Sciences
1.35
-0.13
-8.78%
AVIR
Atea Pharmaceuticals
4.14
1.33
47.33%
OABI
OmniAb
2.29
0.74
47.74%
ProQR Corporate Events
ProQR Posts Q1 2026 Results as Axiomer RNA Editing Pipeline Advances
May 12, 2026
On May 12, 2026, ProQR reported first-quarter 2026 results, highlighting progress across its Axiomer-based pipeline and a solid cash position of €81.1 million, which it says supports operations into mid-2027. The company remains loss-making,...
ProQR Posts Wider Q1 2026 Loss but Maintains Strong Cash Position
May 12, 2026
ProQR reported unaudited financial results for the three months ended March 31, 2026, in a Form 6-K filed on May 12, 2026, along with a business update for the period. The company posted a loss of €13.4 million as revenue declined year-on-ye...
ProQR Sets June 2, 2026 Date for Annual General Meeting of Shareholders
May 4, 2026
On May 4, 2026, ProQR Therapeutics announced that its Annual General Meeting of Shareholders will be held on June 2, 2026, at the offices of Allen Overy Shearman Sterling LLP in Amsterdam, the Netherlands. The company has made the AGM notice, agen...
ProQR Nominates Boehringer Ingelheim CMO Lykke Hinsch Gylvin to Board to Support Next Growth Phase
Apr 30, 2026
On April 30, 2026, ProQR Therapeutics announced the nomination of Dr. Lykke Hinsch Gylvin, Chief Medical Officer and Head of Global Medicine at Boehringer Ingelheim, to its board of directors as an independent non-executive member, pending shareho...
ProQR Details Axiomer Pipeline Expansion and New Liver and Genetic Disease Programs
Apr 8, 2026
On April 8, 2026, ProQR Therapeutics hosted a virtual analyst and investor event titled “Expanding the Axiomer RNA Editing Opportunity Beyond AX-0810” to outline progress across its RNA-editing pipeline. Management highlighted AX-0810 ...
ProQR Partners with Ginkgo Bioworks, Launches AI Advisory Board to Drive Axiomer RNA Drug Discovery
Apr 8, 2026
ProQR Therapeutics, a Netherlands-based RNA biotech specializing in Axiomer RNA base-editing therapies, is expanding its technology platform to target a broad range of rare and common diseases by correcting RNA mutations or modulating protein expr...
ProQR Sets April 8 Virtual Investor Event to Spotlight Axiomer RNA Editing Pipeline
Mar 25, 2026
On March 25, 2026, ProQR Therapeutics announced it will host a virtual Investor and Analyst Event on April 8, 2026, to showcase its expanding pipeline of RNA editing therapies built on the Axiomer platform. The event, titled “Expanding the A...
ProQR Posts 2025 Results as Axiomer RNA Editing Pipeline Advances and Cash Runway Extends to Mid-2027
Mar 12, 2026
On March 12, 2026, ProQR reported its operating and financial results for the year ended Dec. 31, 2025, highlighting progress on lead candidate AX-0810 for cholestatic diseases, which is in an ongoing Phase 1 multiple-dose study in healthy volunte...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.